Gsk (GSK) Operating Interest Expenses (2011 - 2018)

Gsk (GSK) has 6 years of Operating Interest Expenses data on file, last reported at -$711.6 million in Q4 2018.

• For the quarter ending Q4 2018, Operating Interest Expenses rose 19.89% year-over-year to -$711.6 million; the trailing twelve-month figure through Dec 2018 stood at -$3.0 billion (down 17.05% YoY), and the FY2018 full-year result was -$995.0 million, changed N/A from the prior year.
• Operating Interest Expenses was -$711.6 million for Q4 2018 at Gsk, up from -$888.2 million in the prior quarter.
• In the past five years, Operating Interest Expenses ranged from a high of -$270.9 million in Q4 2014 to a low of -$888.2 million in Q4 2017.
• A 3-year average of -$623.6 million and a median of -$711.6 million in 2018 frame the typical range for Operating Interest Expenses.
• Across the five-year window, Operating Interest Expenses soared 75.82% in 2014 and rose 19.89% in 2018, its largest moves.
• Gsk's Operating Interest Expenses stood at -$270.9 million in 2014, then plunged by 227.83% to -$888.2 million in 2017, then grew by 19.89% to -$711.6 million in 2018.
• Per Business Quant data, the three most recent Operating Interest Expenses figures were -$711.6 million in Q4 2018, -$888.2 million in Q4 2017, and -$270.9 million in Q4 2014.